Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Agnes Jager
Observed name:
A. Jager
Institutions:
Erasmus MC,
Erasmus MC Cancer Institute,
Daniel den Hoed Kliniek
Observed institutions:
Erasmus MC,
Erasmus MC Cancer Institute,
Daniel den Hoed Kliniek
OpenAlex ID:
A5130742730
Drug-Drug Interactions in Patients Treated for Cancer: a Prospective Study on Clinical Interventions
2014
·
R.W. van Leeuwen
, F.G.A. Jansman
, et al.
·
Annals of Oncology
·
3
A multigene model for response stratification to neoadjuvant chemotherapy in triple negative breast cancer
2026
·
Nadine S. van den Ende
, Marcel Smid
, et al.
·
The Breast
·
2
PDF
Interactive symptom monitoring and coaching to optimise toxicity management of chemo(immune)therapy in early stage breast cancer: study protocol of the multicentre randomised controlled eChemoCoach trial
2026
·
Rubin J. T. Verduin
, Corina J. G. van den Hurk
, et al.
·
BMC Cancer
·
1
436P SONImage: Can molecular imaging predict outcome to first-line endocrine treatment ± CDK 4/6 inhibition in advanced ER+ breast cancer?
2026
·
J. Moustaquim
, J.J. Knip
, et al.
·
ESMO Open
Outcomes in young germline mutation carriers developing breast cancer while participating in an institutional surveillance program
2026
·
L. Schimmel
, T. Van Dalen
, et al.
·
European Journal of Cancer
Impact of reimbursement on the utilisation of gene expression profiles and chemotherapy decision-making in Dutch breast cancer patients: A population-based study
2026
·
J. Meijer
, N. Hermanns
, et al.
·
European Journal of Cancer
Impact of axillary disease extent defined by baseline 18F-FDG PET/CT on the accuracy of axillary surgical staging after neoadjuvant systemic therapy in clinically node-positive breast cancer
2026
·
Cornelis M. de Mooij
, Janine M. Simons
, et al.
·
The Breast
PDF
2320P Capacity and cost benefits of subcutaneous versus intravenous pertuzumab/trastuzumab: The EASE-SC study
2025
·
M. Zietse
, J. Hu
, et al.
·
Annals of Oncology
The impact of therapeutic drug monitoring-based tamoxifen dose-reductions on endocrine side effects in patients with primary breast cancer
2022
·
S. Buijs
, L. Braal
, et al.
·
European Journal of Cancer
False-Negative Rates Between Pathological Lymph Node Status Between Ductal and Lobular Breast Cancer: A Retrospective Cohort Study of 83,152 Patients
2022
·
A. Oemrawsingh
, A. Heemskerk-Gerritsen
, et al.
·
European Journal of Cancer
Mammacarcinoom
2014
·
A. Jager
, L.B. Koppert
, et al.
·
Bohn Stafleu van Loghum eBooks
4 Mammacarcinoom
2010
·
A. Jager
, M.B.E. Menke-Pluijmers
, et al.
·
Bohn Stafleu van Loghum eBooks
Show more works
View as search
Works count:
12
Citation count:
6
H-index:
2
I10-index:
Year
Topic
Type